Octapharma receives Swissmedic approval for fibryga® to treat congenital and acquired fibrinogen deficiencies - Business Wire

Octapharma receives Swissmedic approval for fibryga® to treat congenital and acquired fibrinogen deficiencies  Business Wire

Octapharma today announced that the Swiss Agency for Therapeutic Products, Swissmedic, granted marketing authorization to its new fibrinogen concentra.